Establishing Patient Centric Specifications for Drug Substance and Drug Product Impurities View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-03

AUTHORS

J. Bercu, S. C. Berlam, J. Berridge, B. Cherney, D. Cowley, H. W. Laughton, D. McLoughlin, M. McMahon, C. M. V. Moore, C. Murti, J. O’Neill, R. Parsons, D. Y. Peng, R. W. Quan, A. K. Subashi, A. Teasdale, S. M. Tyler, T. J. Watson

ABSTRACT

In this paper, we remind readers of several ICH guideline documents such as ICH Q3A, Q3B, Q3C, Q3D, Q6A, Q6B, M7, and ICH S9 which are related to the drug substance and drug product impurity limit setting. In particular, ICH Q6A clearly states that “specifications should focus on those characteristics found to be useful in ensuring the safety and efficacy of the drug substance and drug product”; however, recent negotiations between health authority and applicants (company) related to proposed marketing applications show that on a global level, batch experience, even when limited, plays an overwhelming role in developing impurity acceptance criteria rather than clinical relevance. The drawback of such practice and the great need to establish patient centric specifications (PCS) are highlighted. Secondly, this paper proposes approaches on how to establish patient centric criteria for drug substance and drug product impurity limits based on the principles outlined in ICH guideline documents and scientific literature. Three case studies are presented to illustrate the challenges in establishing PCS and the divergence of regulatory acceptance to such specifications. We propose some approaches that can be considered for specification setting based on clinical relevance in the drug development, registration and post-approval phases of a product life-cycle. Lastly, we give thoughts on the future perspective of this movement and offer recommendations to foster discussions between regulatory agencies and pharmaceutical industry on getting medicinal products that are safe and effective to the patient sooner to meet unmet medical needs without supply interruption concerns. More... »

PAGES

1-14

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12247-018-9366-5

DOI

http://dx.doi.org/10.1007/s12247-018-9366-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1110580607


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Gilead Sciences (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418227.a", 
          "name": [
            "Drug Safety Evaluation, Gilead Sciences, Inc., Foster City, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bercu", 
        "givenName": "J.", 
        "id": "sg:person.01271624440.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01271624440.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer (United States)", 
          "id": "https://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Regulatory CMC, Pfizer, Groton, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Berlam", 
        "givenName": "S. C.", 
        "id": "sg:person.0603430215.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603430215.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Pharmaceutical Quality Consultant, Deal, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Berridge", 
        "givenName": "J.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Quality Assurance, Amgen Inc., Thousand Oaks, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cherney", 
        "givenName": "B.", 
        "id": "sg:person.01027726607.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01027726607.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418152.b", 
          "name": [
            "Development Quality, AstraZeneca, Gaithersburg, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cowley", 
        "givenName": "D.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "Global Chemical Development, AstraZeneca, Macclesfield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Laughton", 
        "givenName": "H. W.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "CMC, Janssen Biologics (Ireland) Limited, Cork, Ireland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McLoughlin", 
        "givenName": "D.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer (United States)", 
          "id": "https://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Regulatory CMC, Pfizer, Groton, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McMahon", 
        "givenName": "M.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "MSD (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417993.1", 
          "name": [
            "Global Regulatory CMC, Merck & Co., West Point, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Moore", 
        "givenName": "C. M. V.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "MSD (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417993.1", 
          "name": [
            "Inc. Global Regulatory CMC, Merck & Co., Rahway, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Murti", 
        "givenName": "C.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Tunnell Consulting, Inc., King of Prussia, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "O\u2019Neill", 
        "givenName": "J.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bristol-Myers Squibb (United States)", 
          "id": "https://www.grid.ac/institutes/grid.419971.3", 
          "name": [
            "Chemical and Synthesis Development, Bristol-Myers Squibb Co., New Brunswick, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Parsons", 
        "givenName": "R.", 
        "id": "sg:person.014702526671.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014702526671.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Drug Product Technical Services, Shire Pharmaceuticals, Exton, PA, USA", 
            "1180 Church Road, 19446, Lansdale, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Peng", 
        "givenName": "D. Y.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AbbVie (United States)", 
          "id": "https://www.grid.ac/institutes/grid.431072.3", 
          "name": [
            "Regulatory CMC, AbbVie, North Chicago, IL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Quan", 
        "givenName": "R. W.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer (United States)", 
          "id": "https://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Regulatory CMC, Pfizer, Groton, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Subashi", 
        "givenName": "A. K.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "Global Chemical Development, AstraZeneca, Macclesfield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Teasdale", 
        "givenName": "A.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AbbVie (United States)", 
          "id": "https://www.grid.ac/institutes/grid.431072.3", 
          "name": [
            "Operations Quality Assurance, AbbVie, North Chicago, IL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tyler", 
        "givenName": "S. M.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer (United States)", 
          "id": "https://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Regulatory CMC, Pfizer, Groton, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Watson", 
        "givenName": "T. J.", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/j.yrtph.2016.12.011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000546754"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/10543406.2014.972511", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001989017"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11095-007-9511-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005521217", 
          "https://doi.org/10.1007/s11095-007-9511-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/op300268u", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1056288371"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ijpharm.2017.06.039", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085988230"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/9781118971147.ch6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092048475"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.yrtph.2018.02.001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100866238"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-03", 
    "datePublishedReg": "2019-03-01", 
    "description": "In this paper, we remind readers of several ICH guideline documents such as ICH Q3A, Q3B, Q3C, Q3D, Q6A, Q6B, M7, and ICH S9 which are related to the drug substance and drug product impurity limit setting. In particular, ICH Q6A clearly states that \u201cspecifications should focus on those characteristics found to be useful in ensuring the safety and efficacy of the drug substance and drug product\u201d; however, recent negotiations between health authority and applicants (company) related to proposed marketing applications show that on a global level, batch experience, even when limited, plays an overwhelming role in developing impurity acceptance criteria rather than clinical relevance. The drawback of such practice and the great need to establish patient centric specifications (PCS) are highlighted. Secondly, this paper proposes approaches on how to establish patient centric criteria for drug substance and drug product impurity limits based on the principles outlined in ICH guideline documents and scientific literature. Three case studies are presented to illustrate the challenges in establishing PCS and the divergence of regulatory acceptance to such specifications. We propose some approaches that can be considered for specification setting based on clinical relevance in the drug development, registration and post-approval phases of a product life-cycle. Lastly, we give thoughts on the future perspective of this movement and offer recommendations to foster discussions between regulatory agencies and pharmaceutical industry on getting medicinal products that are safe and effective to the patient sooner to meet unmet medical needs without supply interruption concerns.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s12247-018-9366-5", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1039359", 
        "issn": [
          "1872-5120", 
          "1939-8042"
        ], 
        "name": "Journal of Pharmaceutical Innovation", 
        "type": "Periodical"
      }
    ], 
    "name": "Establishing Patient Centric Specifications for Drug Substance and Drug Product Impurities", 
    "pagination": "1-14", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "19f9b7e0473f0de1d0d604c6af098815eea537d62c60cdd63c5a7160bde65ebe"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12247-018-9366-5"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1110580607"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12247-018-9366-5", 
      "https://app.dimensions.ai/details/publication/pub.1110580607"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T08:22", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000293_0000000293/records_12005_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs12247-018-9366-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12247-018-9366-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12247-018-9366-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12247-018-9366-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12247-018-9366-5'


 

This table displays all metadata directly associated to this object as RDF triples.

214 TRIPLES      21 PREDICATES      32 URIs      17 LITERALS      5 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12247-018-9366-5 schema:about anzsrc-for:11
2 anzsrc-for:1115
3 schema:author N8af32a390b6248d58444a3be06ff946e
4 schema:citation sg:pub.10.1007/s11095-007-9511-1
5 https://doi.org/10.1002/9781118971147.ch6
6 https://doi.org/10.1016/j.ijpharm.2017.06.039
7 https://doi.org/10.1016/j.yrtph.2016.12.011
8 https://doi.org/10.1016/j.yrtph.2018.02.001
9 https://doi.org/10.1021/op300268u
10 https://doi.org/10.1080/10543406.2014.972511
11 schema:datePublished 2019-03
12 schema:datePublishedReg 2019-03-01
13 schema:description In this paper, we remind readers of several ICH guideline documents such as ICH Q3A, Q3B, Q3C, Q3D, Q6A, Q6B, M7, and ICH S9 which are related to the drug substance and drug product impurity limit setting. In particular, ICH Q6A clearly states that “specifications should focus on those characteristics found to be useful in ensuring the safety and efficacy of the drug substance and drug product”; however, recent negotiations between health authority and applicants (company) related to proposed marketing applications show that on a global level, batch experience, even when limited, plays an overwhelming role in developing impurity acceptance criteria rather than clinical relevance. The drawback of such practice and the great need to establish patient centric specifications (PCS) are highlighted. Secondly, this paper proposes approaches on how to establish patient centric criteria for drug substance and drug product impurity limits based on the principles outlined in ICH guideline documents and scientific literature. Three case studies are presented to illustrate the challenges in establishing PCS and the divergence of regulatory acceptance to such specifications. We propose some approaches that can be considered for specification setting based on clinical relevance in the drug development, registration and post-approval phases of a product life-cycle. Lastly, we give thoughts on the future perspective of this movement and offer recommendations to foster discussions between regulatory agencies and pharmaceutical industry on getting medicinal products that are safe and effective to the patient sooner to meet unmet medical needs without supply interruption concerns.
14 schema:genre research_article
15 schema:inLanguage en
16 schema:isAccessibleForFree false
17 schema:isPartOf sg:journal.1039359
18 schema:name Establishing Patient Centric Specifications for Drug Substance and Drug Product Impurities
19 schema:pagination 1-14
20 schema:productId N443d283e15ba480cb067e24621e51719
21 N6398f8a5e72a4c4294c1070c40e8d85e
22 N6d498344f0eb4b94851b26c93111f9a0
23 schema:sameAs https://app.dimensions.ai/details/publication/pub.1110580607
24 https://doi.org/10.1007/s12247-018-9366-5
25 schema:sdDatePublished 2019-04-11T08:22
26 schema:sdLicense https://scigraph.springernature.com/explorer/license/
27 schema:sdPublisher N8e6747f8eedf47b49c42e091717d00c0
28 schema:url https://link.springer.com/10.1007%2Fs12247-018-9366-5
29 sgo:license sg:explorer/license/
30 sgo:sdDataset articles
31 rdf:type schema:ScholarlyArticle
32 N03343f028e2c438394ebdb45bd1f6e74 rdf:first N8528bf1503f74583a73d44dc47350d34
33 rdf:rest N2691290c918d4aecb6a4b2ba9d30b98c
34 N0351bf6d98224399b0cd8553ddc300a8 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
35 schema:familyName Laughton
36 schema:givenName H. W.
37 rdf:type schema:Person
38 N05e5642bb69c40288c1be59cc1d608c9 schema:affiliation https://www.grid.ac/institutes/grid.431072.3
39 schema:familyName Tyler
40 schema:givenName S. M.
41 rdf:type schema:Person
42 N0f3d75973625404c9223b80abc4bb30b schema:affiliation https://www.grid.ac/institutes/grid.417993.1
43 schema:familyName Murti
44 schema:givenName C.
45 rdf:type schema:Person
46 N1b2bc89a871c43439f7c7fa2b16dddca rdf:first N0351bf6d98224399b0cd8553ddc300a8
47 rdf:rest Nea8dcbfc5ba840cebbfd629a5053c61c
48 N1cd6cead647e429f9bc2c4e28da5bbcf schema:affiliation N90f9c2dbf8444a938d1a7b969ca514db
49 schema:familyName Berridge
50 schema:givenName J.
51 rdf:type schema:Person
52 N20716eeed4d34ad29f912c2bd72a8c78 rdf:first sg:person.01027726607.01
53 rdf:rest N20731098eb254f19b110ba7fb60db65a
54 N20731098eb254f19b110ba7fb60db65a rdf:first N5ecbee842f7c4219959d152eeef1f61e
55 rdf:rest N1b2bc89a871c43439f7c7fa2b16dddca
56 N2691290c918d4aecb6a4b2ba9d30b98c rdf:first Nf70a82ec8f3643099c2938808bb54563
57 rdf:rest N4fb62e83358a43818dd53ee10e474518
58 N2777816e333f42df9320ff254cae6691 rdf:first N0f3d75973625404c9223b80abc4bb30b
59 rdf:rest N63e704b828ca4a17b0e9f53e3659db3b
60 N2f5aa46c820949a0be5f4d450e8f6985 schema:name CMC, Janssen Biologics (Ireland) Limited, Cork, Ireland
61 rdf:type schema:Organization
62 N3da98ec064e44ab2b745b57cde14327b schema:affiliation N2f5aa46c820949a0be5f4d450e8f6985
63 schema:familyName McLoughlin
64 schema:givenName D.
65 rdf:type schema:Person
66 N412964a6f901414fabf907cc3a298e0f rdf:first sg:person.0603430215.48
67 rdf:rest N760dbd5e32b64bebab8c4ba64b970f2c
68 N43ad6a1d30914750b104c3e812a3cc91 schema:name Tunnell Consulting, Inc., King of Prussia, PA, USA
69 rdf:type schema:Organization
70 N443d283e15ba480cb067e24621e51719 schema:name readcube_id
71 schema:value 19f9b7e0473f0de1d0d604c6af098815eea537d62c60cdd63c5a7160bde65ebe
72 rdf:type schema:PropertyValue
73 N4fb62e83358a43818dd53ee10e474518 rdf:first Ne46b60212deb4d7cba86f189182a84fb
74 rdf:rest N705df684c2ea4980a80fc0b80ee3b5a8
75 N5ecbee842f7c4219959d152eeef1f61e schema:affiliation https://www.grid.ac/institutes/grid.418152.b
76 schema:familyName Cowley
77 schema:givenName D.
78 rdf:type schema:Person
79 N6398f8a5e72a4c4294c1070c40e8d85e schema:name dimensions_id
80 schema:value pub.1110580607
81 rdf:type schema:PropertyValue
82 N63e704b828ca4a17b0e9f53e3659db3b rdf:first Nb29cf07cd06145c3a71219636cc2f720
83 rdf:rest Nfc93bc0443a3453d91868f4a40c9bca7
84 N6aa1b00da11c4511a5b46184bc4dba97 schema:affiliation https://www.grid.ac/institutes/grid.417993.1
85 schema:familyName Moore
86 schema:givenName C. M. V.
87 rdf:type schema:Person
88 N6ce99fed28864df79b23baf50645a09f rdf:first N9ddc82f2ddc84f38b8388cb2189999eb
89 rdf:rest rdf:nil
90 N6d498344f0eb4b94851b26c93111f9a0 schema:name doi
91 schema:value 10.1007/s12247-018-9366-5
92 rdf:type schema:PropertyValue
93 N705df684c2ea4980a80fc0b80ee3b5a8 rdf:first N05e5642bb69c40288c1be59cc1d608c9
94 rdf:rest N6ce99fed28864df79b23baf50645a09f
95 N71ad589f5169402ea7ae79a27e1ea61f schema:affiliation N748dd30ba54c4923a9b2ff6768a2997d
96 schema:familyName Peng
97 schema:givenName D. Y.
98 rdf:type schema:Person
99 N748dd30ba54c4923a9b2ff6768a2997d schema:name 1180 Church Road, 19446, Lansdale, PA, USA
100 Drug Product Technical Services, Shire Pharmaceuticals, Exton, PA, USA
101 rdf:type schema:Organization
102 N760dbd5e32b64bebab8c4ba64b970f2c rdf:first N1cd6cead647e429f9bc2c4e28da5bbcf
103 rdf:rest N20716eeed4d34ad29f912c2bd72a8c78
104 N796a9436007a4169bc9ddb11b5c06d0d rdf:first N6aa1b00da11c4511a5b46184bc4dba97
105 rdf:rest N2777816e333f42df9320ff254cae6691
106 N7fb5d383802c4e8d8f79c70e0f7b1340 rdf:first N87401f9b331040e694b27ac8a06b4710
107 rdf:rest N796a9436007a4169bc9ddb11b5c06d0d
108 N8528bf1503f74583a73d44dc47350d34 schema:affiliation https://www.grid.ac/institutes/grid.431072.3
109 schema:familyName Quan
110 schema:givenName R. W.
111 rdf:type schema:Person
112 N87401f9b331040e694b27ac8a06b4710 schema:affiliation https://www.grid.ac/institutes/grid.410513.2
113 schema:familyName McMahon
114 schema:givenName M.
115 rdf:type schema:Person
116 N8af32a390b6248d58444a3be06ff946e rdf:first sg:person.01271624440.19
117 rdf:rest N412964a6f901414fabf907cc3a298e0f
118 N8e6747f8eedf47b49c42e091717d00c0 schema:name Springer Nature - SN SciGraph project
119 rdf:type schema:Organization
120 N90f9c2dbf8444a938d1a7b969ca514db schema:name Pharmaceutical Quality Consultant, Deal, UK
121 rdf:type schema:Organization
122 N9ddc82f2ddc84f38b8388cb2189999eb schema:affiliation https://www.grid.ac/institutes/grid.410513.2
123 schema:familyName Watson
124 schema:givenName T. J.
125 rdf:type schema:Person
126 Nac607e7736864e649cd0f38d8e9be7eb rdf:first N71ad589f5169402ea7ae79a27e1ea61f
127 rdf:rest N03343f028e2c438394ebdb45bd1f6e74
128 Nb29cf07cd06145c3a71219636cc2f720 schema:affiliation N43ad6a1d30914750b104c3e812a3cc91
129 schema:familyName O’Neill
130 schema:givenName J.
131 rdf:type schema:Person
132 Ne46b60212deb4d7cba86f189182a84fb schema:affiliation https://www.grid.ac/institutes/grid.417815.e
133 schema:familyName Teasdale
134 schema:givenName A.
135 rdf:type schema:Person
136 Nea8dcbfc5ba840cebbfd629a5053c61c rdf:first N3da98ec064e44ab2b745b57cde14327b
137 rdf:rest N7fb5d383802c4e8d8f79c70e0f7b1340
138 Nf70a82ec8f3643099c2938808bb54563 schema:affiliation https://www.grid.ac/institutes/grid.410513.2
139 schema:familyName Subashi
140 schema:givenName A. K.
141 rdf:type schema:Person
142 Nfc93bc0443a3453d91868f4a40c9bca7 rdf:first sg:person.014702526671.22
143 rdf:rest Nac607e7736864e649cd0f38d8e9be7eb
144 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
145 schema:name Medical and Health Sciences
146 rdf:type schema:DefinedTerm
147 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
148 schema:name Pharmacology and Pharmaceutical Sciences
149 rdf:type schema:DefinedTerm
150 sg:journal.1039359 schema:issn 1872-5120
151 1939-8042
152 schema:name Journal of Pharmaceutical Innovation
153 rdf:type schema:Periodical
154 sg:person.01027726607.01 schema:affiliation https://www.grid.ac/institutes/grid.417886.4
155 schema:familyName Cherney
156 schema:givenName B.
157 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01027726607.01
158 rdf:type schema:Person
159 sg:person.01271624440.19 schema:affiliation https://www.grid.ac/institutes/grid.418227.a
160 schema:familyName Bercu
161 schema:givenName J.
162 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01271624440.19
163 rdf:type schema:Person
164 sg:person.014702526671.22 schema:affiliation https://www.grid.ac/institutes/grid.419971.3
165 schema:familyName Parsons
166 schema:givenName R.
167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014702526671.22
168 rdf:type schema:Person
169 sg:person.0603430215.48 schema:affiliation https://www.grid.ac/institutes/grid.410513.2
170 schema:familyName Berlam
171 schema:givenName S. C.
172 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603430215.48
173 rdf:type schema:Person
174 sg:pub.10.1007/s11095-007-9511-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005521217
175 https://doi.org/10.1007/s11095-007-9511-1
176 rdf:type schema:CreativeWork
177 https://doi.org/10.1002/9781118971147.ch6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092048475
178 rdf:type schema:CreativeWork
179 https://doi.org/10.1016/j.ijpharm.2017.06.039 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085988230
180 rdf:type schema:CreativeWork
181 https://doi.org/10.1016/j.yrtph.2016.12.011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000546754
182 rdf:type schema:CreativeWork
183 https://doi.org/10.1016/j.yrtph.2018.02.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100866238
184 rdf:type schema:CreativeWork
185 https://doi.org/10.1021/op300268u schema:sameAs https://app.dimensions.ai/details/publication/pub.1056288371
186 rdf:type schema:CreativeWork
187 https://doi.org/10.1080/10543406.2014.972511 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001989017
188 rdf:type schema:CreativeWork
189 https://www.grid.ac/institutes/grid.410513.2 schema:alternateName Pfizer (United States)
190 schema:name Regulatory CMC, Pfizer, Groton, CT, USA
191 rdf:type schema:Organization
192 https://www.grid.ac/institutes/grid.417815.e schema:alternateName AstraZeneca (United Kingdom)
193 schema:name Global Chemical Development, AstraZeneca, Macclesfield, UK
194 rdf:type schema:Organization
195 https://www.grid.ac/institutes/grid.417886.4 schema:alternateName Amgen (United States)
196 schema:name Quality Assurance, Amgen Inc., Thousand Oaks, CA, USA
197 rdf:type schema:Organization
198 https://www.grid.ac/institutes/grid.417993.1 schema:alternateName MSD (United States)
199 schema:name Global Regulatory CMC, Merck & Co., West Point, PA, USA
200 Inc. Global Regulatory CMC, Merck & Co., Rahway, NJ, USA
201 rdf:type schema:Organization
202 https://www.grid.ac/institutes/grid.418152.b schema:alternateName AstraZeneca (United States)
203 schema:name Development Quality, AstraZeneca, Gaithersburg, MD, USA
204 rdf:type schema:Organization
205 https://www.grid.ac/institutes/grid.418227.a schema:alternateName Gilead Sciences (United States)
206 schema:name Drug Safety Evaluation, Gilead Sciences, Inc., Foster City, CA, USA
207 rdf:type schema:Organization
208 https://www.grid.ac/institutes/grid.419971.3 schema:alternateName Bristol-Myers Squibb (United States)
209 schema:name Chemical and Synthesis Development, Bristol-Myers Squibb Co., New Brunswick, NJ, USA
210 rdf:type schema:Organization
211 https://www.grid.ac/institutes/grid.431072.3 schema:alternateName AbbVie (United States)
212 schema:name Operations Quality Assurance, AbbVie, North Chicago, IL, USA
213 Regulatory CMC, AbbVie, North Chicago, IL, USA
214 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...